🔗 Share this article

A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on communication apps, according to recent findings.

Investigational Drug Gaining Popularity Online

Retatrutide, which remains in clinical trials, is being promoted by social media influencers for its supposed weight-reducing properties. Followers are encouraged to contact these profiles privately for supplier links, while also obtaining discount codes.

Thriving Trade on Social Networks

Additionally, a robust market exists on messaging services, where communities with numerous of members share “before and after” images, injection guides and assertions of rapid British shipping. Sellers promote the substance there before redirecting customers to WhatsApp for transactions.

Learning About The Experimental Drug

This medication is an investigational injectable created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, GIP and pancreatic hormone. Early trials indicate it could help individuals reduce up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Healthcare Experts Voice Concerns

However, doctors and pharmacists have warned that the distribution of what is still an unapproved drug in the UK is a cause for concern and could result in users administering substances of uncertain source.

Several experts said the demand for retatrutide could be linked to the rising cost of licensed slimming treatments such as Mounjaro.

Regulatory Position and Implementation

Marketing retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed drug that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several influencers try to sidestep the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach medicines, marketing, and consumer regulations, risking fines, prosecution or prison.

Service Response and Material Elimination

Based on the social media company, the platform has taken down violative content and prohibited related hashtags and query recommendations. The organization said it was dedicated to keeping the platform safe and investing in strengthening compliance measures.

Digital Trading Activities

Investigations also discovered groups with up to 9,000 participants selling the experimental drug using the platform's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately brings up channels with numerous of members, filled with images of slimming results, glowing reviews and step-by-step guides for mixing or administering at residence.

Within minutes of joining one community, a vendor shared WhatsApp details, where most transactions occur. The vendor provided an instruction manual and promised delivery within two days. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one asked about weight, health issues or past usage.

Item Information and Pricing

Within these communities, posts show black plastic parcels with Royal Mail labels, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at home with purified liquid, or pre-filled pens typically priced at £160 for 20mg. When asked how much time a pen should be used, vendors give contradictory responses varying between a few weeks to “depends on your body”.

Platform Moderation and Safety Measures

A spokesperson for Telegram said it actively monitored harmful material on its platform including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are administering materials they cannot confirm. Although the research behind this drug is valid, these online products may not contain what they claim,” stated Jason Murphy, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent cost increases for approved slimming drugs such as Mounjaro. “With prices rising, individuals are turning to online platforms. But counterfeit treatments are extremely risky. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she explained.

Her team has previously seen patients harmed by personal administration from unconfirmed suppliers. “We recognize the frustration, but purchasing from Telegram or WhatsApp is gambling with your well-being,” stated Wyllie. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A representative from Eli Lilly said retatrutide was in third stage clinical trials and had not been reviewed or approved by any regulatory agency globally. “Consequently at this time no one can market [it] for human use,” they explained, noting that any product “falsely representing itself as a company investigational product not yet authorized … may expose users to possibly significant health risks”.